FA
ALXN

Friess Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Friess Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-58,235
Closed -$8.17M – 132
2017
Q3 		$8.17M Buy
58,235
+1,335
+2% +$181K 0.72% 65
2017
Q2 		$6.92M Buy
+56,900
New +$6.62M 0.63% 69
2015
Q2 		– Sell
-99,100
Closed -$17.2M – 174
2015
Q1 		$17.2M Buy
99,100
+69,100
+230% +$12.5M 1.39% 31
2014
Q4 		$5.55M Buy
+30,000
New +$5.56M 0.45% 73

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Friess Associates's ALXN Position: Q4 2017 in Review

Friess Associates sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 58,235 shares — an estimated $8.17M sold.

Friess Associates first reported a position in ALXN in Q4 2014 and held it in 4 quarters. The position peaked at $17.2M in Q1 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Friess Associates reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Friess Associates sold 58,235 Alexion Pharmaceuticals shares in Q4 2017, an estimated $8.17M.
  • Friess Associates first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Friess Associates's Alexion Pharmaceuticals position peaked at $17.2M in Q1 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Friess Associates's 13F filing for Q4 2017, filed 14 Feb 2018.